missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Aurora A/B/C Antibody (4A7), Alexa Fluor™ 405, Novus Biologicals™
Mouse Monoclonal Antibody
Brand: Novus Biologicals NBP2-50046AF405
This item is not returnable.
View return policy
Description
Aurora A/B/C Monoclonal antibody specifically detects Aurora A/B/C in Human, Mouse, Rat, Porcine, Bovine, Equine samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence
Specifications
| Aurora A/B/C | |
| Monoclonal | |
| Alexa Fluor 405 | |
| AIE2, AIK, AIK2, AIK3, AIM1, AIM-1, ARK1, ARK2, ARK-2, ARK3, ARK-3, AURA, AurB, AurC, aurkb-sv1, aurkb-sv2, aurora 2, aurora 3, aurora- and Ipl1-like midbody-associated protein 1, aurora kinase A, aurora kinase B, aurora kinase B-Sv1, aurora kinase B-Sv2, aurora kinase C, aurora/IPL1/EG2 protein 2, aurora/IPL1-like kinase, aurora/IPL1-related kinase 1, aurora/IPL1-related kinase 2, aurora/IPL1-related kinase 3, aurora-1, aurora-B, aurora-C, aurora-related kinase 2, aurora-related kinase 3, breast tumor-amplified kinase, BTAK, epididymis secretory protein Li 90, HEL-S-90, IPL1, PPP1R47, PPP1R48, protein phosphatase 1, regulatory subunit 47, protein phosphatase 1, regulatory subunit 48, serine/threonine kinase 12, serine/threonine kinase 13 (aurora/IPL1-like), serine/threonine protein kinase 15, serine/threonine-protein kinase 12, serine/threonine-protein kinase 13, serine/threonine-protein kinase 5, serine/threonine-protein kinase 6, serine/threonine-protein kinase aurora-A, serine/thr | |
| Full length recombinant human AURKA protein expressed from E. coli. | |
| 0.1 mL | |
| Primary | |
| Store at 4°C in the dark. | |
| IgG1 |
| Western Blot, Immunohistochemistry, Immunofluorescence | |
| 4A7 | |
| 50 mM Sodium Borate | |
| Mouse | |
| Protein G purified | |
| RUO | |
| Human, Mouse, Rat, Pig, Bovine | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction